Differential effects of amphotericin B and liposomal amphotericin B on inflammatory cells in vitro

Inflammation Research

Volumn 51, Issue 5, 2002, Pages 259-264

  Baronti, R ^a   Masini, E ^a   Bacciottini, L ^a   Mannaioni, P F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

AraB; Basophils; Immuno allergic reactions; Liposomal AmB; Mast cells

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CD63 ANTIGEN; DEOXYCHOLIC ACID; HISTAMINE; IMMUNOGLOBULIN E; LACTATE DEHYDROGENASE; LIPOSOME;

ALLERGIC REACTION; ANIMAL CELL; ARTICLE; BASOPHIL; CONTROLLED STUDY; CYTOFLUOROMETRY; DENSITY GRADIENT CENTRIFUGATION; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY CELL; MAST CELL; NONHUMAN; RAT; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PHENOTYPE;

AMPHOTERICIN B; ANIMALS; BASOPHILS; CENTRIFUGATION, DENSITY GRADIENT; DEOXYCHOLIC ACID; HISTAMINE RELEASE; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; L-LACTATE DEHYDROGENASE; LIPOSOMES; MAST CELLS; PHENOTYPE; RATS;

EID: 0035999586     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000302     Document Type: Article

References (21)

1. Amphotericin A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies
2. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology
3. Amphotericin versus pentamidine in antimony-unresponsive kala-azar
4. Liposomal amphotericin B (ambisome): Safety data from a phase II/III clinical trial
5. Amphotericin B and other polyenic antifungal antibiotics
6. Amphotericin B: New life for an old drug
7. Lipid formulation of amphotericin B. Less toxicity but at what economic cost?
8. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes
9. Development, characterization, efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B
10. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
11. Incompatibility of reconstituted aqueous amphotericin B with fat emulsion (II)
12. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: Randomized study
13. Plenary lecture. Mast cells revisited
14. A method for the fluorimetric assay of histamine in tissues
15. A procedure for the determination of histamine
16. Pharmacokinetics of liposomal amphotericin B (ambisome) in critically ill patients
17. Activation of mast cells by bile acids
18. Helicobacter pylori potentiates histamine release from rat serosal mast cells induced by bile acids
19. The polyenes
20. Overview of the treatment of disseminated fungal infections
21. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes